The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

On November 29, 2006 Federal advisers recommended that Pfizer Inc. can market their painkiller Celebrex to children with rheumatoid arthritis. The Food and drug Administration now is faced with making a decision of whether they will expand the approval of Celebrex.

The advisers said that the benefit’s outweighed the risks in a 15 to 1 vote. Celebrex is also a Cox 2 inhibitor drug along with Vioxx and Bextra, both of which have been removed from the market due to increased risk of heart attack and/or stroke. The long term safety for children is unknown therefore the panel advised Pfizer to conduct a long term study. They have stated that short term use has had no ill effects. Hopefully for children suffering from this disease this will help them and not hurt them, I guess we will have to wait and see.

Comments are closed.

Of Interest